Adimmune Corporation (4142.TW)
TWD 18.85
(-3.83%)
TWD 18.85
(-3.83%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -722.74 Million TWD | -493.24% |
| 2022 | 183.79 Million TWD | 534.36% |
| 2021 | 28.97 Million TWD | -97.62% |
| 2020 | 1.21 Billion TWD | 545.81% |
| 2019 | -273.53 Million TWD | 61.82% |
| 2018 | -716.48 Million TWD | -1.6% |
| 2017 | -705.22 Million TWD | -19.15% |
| 2016 | -591.87 Million TWD | 19.75% |
| 2015 | -737.52 Million TWD | -13.89% |
| 2014 | -647.6 Million TWD | -0.17% |
| 2013 | -646.48 Million TWD | 3.0% |
| 2012 | -666.48 Million TWD | -14.69% |
| 2011 | -581.11 Million TWD | -363.13% |
| 2010 | 220.84 Million TWD | -70.18% |
| 2009 | 740.61 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -195.21 Million TWD | 49.14% |
| 2024 Q2 | -291.97 Million TWD | -49.57% |
| 2023 Q4 | -383.8 Million TWD | -210.44% |
| 2023 FY | -722.74 Million TWD | -493.24% |
| 2023 Q3 | 347.51 Million TWD | 244.3% |
| 2023 Q1 | -263.59 Million TWD | -962.73% |
| 2023 Q2 | -240.82 Million TWD | 8.64% |
| 2022 FY | 183.79 Million TWD | 534.36% |
| 2022 Q1 | -244.63 Million TWD | -181.96% |
| 2022 Q2 | -15.6 Million TWD | 93.62% |
| 2022 Q4 | 30.55 Million TWD | -92.61% |
| 2022 Q3 | 413.47 Million TWD | 2750.46% |
| 2021 FY | 28.97 Million TWD | -97.62% |
| 2021 Q4 | 298.45 Million TWD | 88.6% |
| 2021 Q1 | -277.85 Million TWD | -2225.55% |
| 2021 Q2 | -214.51 Million TWD | 22.8% |
| 2021 Q3 | 158.24 Million TWD | 173.77% |
| 2020 Q3 | 137.37 Million TWD | 187.65% |
| 2020 Q2 | -156.73 Million TWD | -702.53% |
| 2020 Q1 | -19.53 Million TWD | 8.01% |
| 2020 Q4 | 13.07 Million TWD | -90.48% |
| 2020 FY | 1.21 Billion TWD | 545.81% |
| 2019 Q3 | 101.62 Million TWD | 156.56% |
| 2019 FY | -273.53 Million TWD | 61.82% |
| 2019 Q1 | -199.7 Million TWD | 43.92% |
| 2019 Q2 | -179.67 Million TWD | 10.03% |
| 2019 Q4 | -21.23 Million TWD | -120.89% |
| 2018 Q3 | -26.92 Million TWD | 82.59% |
| 2018 FY | -716.48 Million TWD | -1.6% |
| 2018 Q4 | -356.11 Million TWD | -1222.68% |
| 2018 Q2 | -154.68 Million TWD | 13.47% |
| 2018 Q1 | -178.76 Million TWD | 1.15% |
| 2017 Q2 | -231.09 Million TWD | -23.71% |
| 2017 FY | -705.22 Million TWD | -19.15% |
| 2017 Q3 | -106.48 Million TWD | 53.92% |
| 2017 Q1 | -186.8 Million TWD | 3.98% |
| 2017 Q4 | -180.83 Million TWD | -69.82% |
| 2016 Q3 | -127.09 Million TWD | 1.25% |
| 2016 FY | -591.87 Million TWD | 19.75% |
| 2016 Q1 | -141.52 Million TWD | 50.95% |
| 2016 Q2 | -128.7 Million TWD | 9.06% |
| 2016 Q4 | -194.54 Million TWD | -53.07% |
| 2015 Q4 | -288.53 Million TWD | -47.19% |
| 2015 FY | -737.52 Million TWD | -13.89% |
| 2015 Q3 | -196.03 Million TWD | -90.87% |
| 2015 Q1 | -150.26 Million TWD | 39.77% |
| 2015 Q2 | -102.7 Million TWD | 31.65% |
| 2014 Q3 | -198.18 Million TWD | -266.49% |
| 2014 Q4 | -249.48 Million TWD | -25.89% |
| 2014 Q1 | -145.85 Million TWD | 40.94% |
| 2014 FY | -647.6 Million TWD | -0.17% |
| 2014 Q2 | -54.07 Million TWD | 62.92% |
| 2013 Q3 | -99.82 Million TWD | 24.47% |
| 2013 Q1 | -167.55 Million TWD | 11.88% |
| 2013 FY | -646.48 Million TWD | 3.0% |
| 2013 Q4 | -246.95 Million TWD | -147.39% |
| 2013 Q2 | -132.16 Million TWD | 21.12% |
| 2012 Q2 | -152.34 Million TWD | 6.16% |
| 2012 Q4 | -190.14 Million TWD | -16.33% |
| 2012 Q3 | -163.45 Million TWD | -7.29% |
| 2012 Q1 | -162.33 Million TWD | 17.23% |
| 2012 FY | -666.48 Million TWD | -14.69% |
| 2011 Q3 | -128.13 Million TWD | 24.61% |
| 2011 FY | -581.11 Million TWD | -363.13% |
| 2011 Q4 | -196.11 Million TWD | -53.06% |
| 2011 Q2 | -169.95 Million TWD | -95.57% |
| 2011 Q1 | -86.9 Million TWD | 20.94% |
| 2010 Q3 | -116.05 Million TWD | 0.0% |
| 2010 FY | 220.84 Million TWD | -70.18% |
| 2010 Q4 | -109.92 Million TWD | 5.28% |
| 2009 FY | 740.61 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 141.71 Million TWD | 609.997% |
| Sinphar Pharmaceutical Co.,Ltd. | 286.05 Million TWD | 352.659% |
| Panion & Bf Biotech Inc. | 156.82 Million TWD | 560.85% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 280.8 Million TWD | 357.38% |
| GenMont Biotech Incorporation | 6.98 Million TWD | 10442.687% |
| Abnova (Taiwan) Corporation | 47.19 Million TWD | 1631.438% |
| Tanvex BioPharma, Inc. | -2.1 Billion TWD | 65.596% |
| Polaris Group | -1.84 Billion TWD | 60.87% |
| Energenesis Biomedical CO.,LTD. | -261.83 Million TWD | -176.029% |
| UnicoCell Biomed Co., Ltd. | -96.28 Million TWD | -650.672% |
| PELL Bio-Med Technology Co. Ltd. | -411.24 Million TWD | -75.746% |